Zasocitinib Explained
Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various inflammatory conditions including psoriatic arthritis and Crohn's disease.[1] [2] [3] It is significantly more selective than earlier compounds over side targets such as JAK1, which is hoped to give it an improved side effect profile.[4]
See also
Notes and References
- Leit S, Greenwood J, Carriero S, Mondal S, Abel R, Ashwell M, Blanchette H, Boyles NA, Cartwright M, Collis A, Feng S, Ghanakota P, Harriman GC, Hosagrahara V, Kaila N, Kapeller R, Rafi SB, Romero DL, Tarantino PM, Timaniya J, Toms AV, Wester RT, Westlin W, Srivastava B, Miao W, Tummino P, McElwee JJ, Edmondson SD, Masse CE . Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279 . Journal of Medicinal Chemistry . 66 . 15 . 10473–10496 . August 2023 . 37427891 . 10.1021/acs.jmedchem.3c00600 .
- The investigational tyrosine kinase inhibitor TAK-279 is effective and well tolerated in patients with active psoriatic arthritis in phase 2b study. . Kivitz AJ . Cleveland Clinic Journal of Medicine . 14 November 2023 .
- Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis. . Kivitz A, Muensterman ET, Kavanaugh A, Van der Heijde D, Klimiuk PA, Valenzuela G, Dokoupilova E, Poirier G . American College of Rheumatology . 24 October 2023 .
- Web site: The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda. . synapse.patsnap.com . 10 August 2023 .
